The lipogenic regulator SREBF2 induces Transferrin in circulating melanoma cells and suppresses ferroptosis.

Circulating tumor cells (CTCs) are shed by cancer into the bloodstream, where a viable subset overcomes oxidative stress to initiate metastasis. We show that single CTCs from melanoma patients coordinately upregulate lipogenesis and iron homeostasis pathways. These are correlated with both intrinsic and acquired resistance to BRAF inhibitors across clonal cultures of BRAF-mutant CTCs. The lipogenesis regulator SREBF2 directly induces transcription of the iron carrier Transferrin (TF), reducing intracellular iron pools, reactive oxygen species (ROS) and lipid peroxidation, thereby conferring resistance to inducers of ferroptosis. Knockdown of endogenous TF impairs tumor formation by melanoma CTCs, and their tumorigenic defects are partially rescued by the lipophilic anti-oxidants Ferrostatin-1 and Vitamin E. In a prospective melanoma cohort, presence of CTCs with high lipogenic and iron metabolic RNA signatures is correlated with adverse clinical outcome, irrespective of treatment regimen. Thus, SREBF2-driven iron homeostatic pathways contribute to cancer progression, drug resistance and metastasis.

[1]  S. Morrison,et al.  Lymph protects metastasizing melanoma cells from ferroptosis , 2020, Nature.

[2]  Martin L. Miller,et al.  UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma , 2019, Cell.

[3]  Ben S. Wittner,et al.  Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer , 2019, npj Precision Oncology.

[4]  T. Vanden Berghe,et al.  Targeting Ferroptosis to Iron Out Cancer. , 2019, Cancer cell.

[5]  A. Chinnaiyan,et al.  CD8+ T cells regulate tumor ferroptosis during cancer immunotherapy , 2019, Nature.

[6]  O. Abdel-Rahman,et al.  Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies , 2018, Clinical and Translational Oncology.

[7]  Paul J. Hoover,et al.  Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma , 2018, Cell.

[8]  P. Agostinis,et al.  Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy , 2018, Nature Communications.

[9]  G. Mills,et al.  Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. , 2018, Cancer cell.

[10]  T. Graeber,et al.  Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. , 2018, Cancer cell.

[11]  Linda T. Nieman,et al.  Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy , 2018, Proceedings of the National Academy of Sciences.

[12]  J. Clohessy,et al.  An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer , 2018, Nature Genetics.

[13]  P. Shang,et al.  Transferrin receptor 1 in cancer: a new sight for cancer therapy. , 2018, American journal of cancer research.

[14]  D. Haber,et al.  Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells , 2017, Nature Communications.

[15]  B. Stockwell,et al.  Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease , 2017, Cell.

[16]  Tahmina Nasrin Poly,et al.  Exploring association between statin use and breast cancer risk: an updated meta-analysis , 2017, Archives of Gynecology and Obstetrics.

[17]  Stuart L. Schreiber,et al.  Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition , 2017, Nature.

[18]  H. Shimano,et al.  SREBP-regulated lipid metabolism: convergent physiology — divergent pathophysiology , 2017, Nature Reviews Endocrinology.

[19]  Harini Veeraraghavan,et al.  Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient , 2017, Cell.

[20]  D. Nam,et al.  RNF20 Suppresses Tumorigenesis by Inhibiting the SREBP1c-PTTG1 Axis in Kidney Cancer , 2017, Molecular and Cellular Biology.

[21]  Jill P. Mesirov,et al.  Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway , 2017, Nature.

[22]  F. Ma,et al.  The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis , 2017, Breast Cancer Research and Treatment.

[23]  Sridhar Ramaswamy,et al.  Expression of β-globin by cancer cells promotes cell survival during blood-borne dissemination , 2017, Nature Communications.

[24]  J. Neuzil,et al.  Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism , 2016, Oncotarget.

[25]  M. Postow Faculty Opinions recommendation of PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2016 .

[26]  Yu Shyr,et al.  Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade , 2016, Cancer Immunology Research.

[27]  Wei Huang,et al.  SREBP-1 is an independent prognostic marker and promotes invasion and migration in breast cancer , 2016, Oncology letters.

[28]  Sridhar Ramaswamy,et al.  HER2 expression identifies dynamic functional states within circulating breast cancer cells , 2016, Nature.

[29]  D. Haber,et al.  Single-Cell Analysis of Circulating Tumor Cells as a Window into Tumor Heterogeneity. , 2016, Cold Spring Harbor symposia on quantitative biology.

[30]  Eugenia G. Giannopoulou,et al.  Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH , 2015, Science.

[31]  M. Bergo,et al.  Antioxidants can increase melanoma metastasis in mice , 2015, Science Translational Medicine.

[32]  R. Deberardinis,et al.  Oxidative stress inhibits distant metastasis by human melanoma cells , 2015, Nature.

[33]  Sridhar Ramaswamy,et al.  RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance , 2015, Science.

[34]  Minghui Gao,et al.  Glutaminolysis and Transferrin Regulate Ferroptosis. , 2015, Molecular cell.

[35]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[36]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[38]  I. Ben-Sahra,et al.  Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP , 2015, Oncogene.

[39]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[40]  D. Schadendorf,et al.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[42]  Antoni Ribas,et al.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.

[43]  Kate B. Cook,et al.  Determination and Inference of Eukaryotic Transcription Factor Sequence Specificity , 2014, Cell.

[44]  Sridhar Ramaswamy,et al.  Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis , 2014, Cell.

[45]  Sridhar Ramaswamy,et al.  Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility , 2014, Science.

[46]  Ben S. Wittner,et al.  Abstract 4832: Isolation and molecular characterization of circulating melanoma cells , 2014 .

[47]  P. Mischel,et al.  Targeting SREBP-1-driven lipid metabolism to treat cancer. , 2014, Current pharmaceutical design.

[48]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Eugene J. Lim,et al.  Microfluidic, marker-free isolation of circulating tumor cells from blood samples , 2014, Nature Protocols.

[50]  S. Bonovas,et al.  Statins and the risk of colorectal cancer: an updated systematic review and meta-analysis of 40 studies. , 2014, World journal of gastroenterology.

[51]  A. Bovier,et al.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? , 2013, Nature Reviews Cancer.

[52]  Pau-Chung Chen,et al.  Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Mehmet Toner,et al.  Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells , 2013, Science Translational Medicine.

[54]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[55]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[56]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[57]  M. R. Lamprecht,et al.  Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death , 2012, Cell.

[58]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[59]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[60]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[61]  Mehmet Toner,et al.  Circulating tumor cells: approaches to isolation and characterization , 2011, The Journal of cell biology.

[62]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[63]  S. Horvath,et al.  EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy , 2009, Science Signaling.

[64]  T. Furukawa,et al.  Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. , 2008, Carcinogenesis.

[65]  B. Stockwell,et al.  Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. , 2008, Chemistry & biology.

[66]  R. Meacham,et al.  Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. , 2008, Cancer research.

[67]  Anne E Carpenter,et al.  A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen , 2006, Cell.

[68]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[69]  T. Osborne,et al.  Selective Coactivator Interactions in Gene Activation by SREBP-1a and -1c , 2004, Molecular and Cellular Biology.

[70]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[71]  Jay D. Horton,et al.  Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[72]  P. Arosio,et al.  Ferritin, iron homeostasis, and oxidative damage. , 2002, Free radical biology & medicine.

[73]  D. Calvisi,et al.  Transferrin and transferrin receptor gene expression and iron uptake in hepatocellular carcinoma in the rat , 1998, Hepatology.

[74]  J. Zweier,et al.  Mitogenic Signaling Mediated by Oxidants in Ras-Transformed Fibroblasts , 1997, Science.

[75]  Felix Kratz,et al.  Transferrin: From Inorganic Biochemistry to Medicine , 1994, Metal-based drugs.

[76]  B. Bloch,et al.  Transferrin gene expression visualized in oligodendrocytes of the rat brain by using in situ hybridization and immunohistochemistry. , 1985, Proceedings of the National Academy of Sciences of the United States of America.